274 related articles for article (PubMed ID: 28544782)
1. Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial.
Rozemeijer R; Stein M; Frambach P; Voskuil M; Kraaijeveld AO; Rodríguez-Olivares R; Timmers L; Pereira B; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
Catheter Cardiovasc Interv; 2018 Feb; 91(3):410-416. PubMed ID: 28544782
[TBL] [Abstract][Full Text] [Related]
2. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
Rozemeijer R; Benedetto D; Kraaijeveld AO; Voskuil M; Stein M; Timmers L; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):521-525. PubMed ID: 29137966
[TBL] [Abstract][Full Text] [Related]
4. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
5. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
[TBL] [Abstract][Full Text] [Related]
6. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
[TBL] [Abstract][Full Text] [Related]
7. 3-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis.
van Hemert ND; Voskuil M; Rozemeijer R; Stein M; Frambach P; Pereira B; Rittersma SZ; Kraaijeveld AO; Leenders GEH; Timmers L; van der Harst P; Agostoni P; Stella PR;
JACC Cardiovasc Interv; 2021 Nov; 14(22):2477-2486. PubMed ID: 34794654
[TBL] [Abstract][Full Text] [Related]
8. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
9. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R; van Muiden IG; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Doevendans PA; Voskuil M; Stella PR
Catheter Cardiovasc Interv; 2019 Jul; 94(1):61-69. PubMed ID: 30604493
[TBL] [Abstract][Full Text] [Related]
10. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
11. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
12. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
13. Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial.
Lee JM; Park SD; Lim SY; Doh JH; Cho JM; Kim KS; Bae JW; Chung WY; Youn TJ
Trials; 2013 Nov; 14():398. PubMed ID: 24257456
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
15. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
16. Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials.
Konigstein M; Smits PC; Love MP; Ben-Yehuda O; Ozan MO; Liu M; Perlman GY; Leon MB; Stone GW; Kandzari DE
JACC Cardiovasc Interv; 2020 Jan; 13(1):86-93. PubMed ID: 31918946
[TBL] [Abstract][Full Text] [Related]
17. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
[TBL] [Abstract][Full Text] [Related]
18. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
[TBL] [Abstract][Full Text] [Related]
19. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
[TBL] [Abstract][Full Text] [Related]
20. Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials.
Ploumen EH; Buiten RA; Kok MM; Doggen CJM; Roguin A; Jessurun GAJ; Schotborgh CE; Danse PW; Benit E; Aminian A; van Houwelingen KG; Stoel MG; Scholte M; Hartmann M; Linssen GCM; Zocca P; von Birgelen C
Int J Cardiol; 2021 Feb; 325():37-44. PubMed ID: 33148427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
